Skip to content

Study · Non-randomized trial · n = 5 · 2001

7 results

Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.

Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ, van der Lely AJ

The Journal of clinical endocrinology and metabolism1 Feb 2001Cited by 37 (Europe PMC)

PMID11158013 (opens in a new tab)DOI10.1210/jcem.86.2.7173 (opens in a new tab)PepBankPUB-11158013
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy nonobese men, GHRP-6 increased serum insulin during nonfasting pegvisomant blockade, unlike conditions without pegvisomant.

    In plain wordsIn healthy men, GHRP-6 raised insulin during nonfasting pegvisomant blockade, unlike conditions without pegvisomant.

    Peptide
    Pegvisomant
    Outcome
    IncreaseSerum insulin response to GHRP-6
    Study

    n = 5

    Comparator
    Absence of pegvisomant under nonfasting conditions
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Serum insulin before challenge
    10.3 mU/L
    nonfasting pegvisomant blockade
    Serum insulin variability before challenge
    2.1 mU/L
    nonfasting pegvisomant blockade, plus or minus
    Serum insulin after challenge
    81.3 mU/L
    nonfasting pegvisomant blockade
    Serum insulin variability after challenge
    25.4 mU/L
    nonfasting pegvisomant blockade, plus or minus
    P value
    < 0.001
    insulin, nonfasting pegvisomant blockade

    Source sentences

    Summary
    Under the condition of GHR blockade by pegvisomant in the nonfasting state, GHRP-6 (1 microg/kg) caused a increase in serum insulin (10.3 +/- 2.1 vs. 81.3 +/- 25.4 mU/L; P < 0.001)
    3 context sentences
    Summary · context
    These changes were not observed under GHR blockade during fasting or in the absence of pegvisomant.
    Summary · context
    We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in fasting and nonfasting conditions.
    Summary · context
    Ten healthy subjects were enrolled in a double blind, placebo-controlled study on the effects of pegvisomant on GHRH and GH-releasing peptide-6 (GHRP-6)-induced GH secretion before and after 3 days of fasting and under nonfasting conditions (n = 5).
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy nonobese men, GHRP-6 increased serum glucose during nonfasting pegvisomant blockade, unlike conditions without pegvisomant.

    In plain wordsIn healthy men, GHRP-6 raised glucose during nonfasting pegvisomant blockade, unlike conditions without pegvisomant.

    Peptide
    Pegvisomant
    Outcome
    IncreaseSerum glucose response to GHRP-6
    Study

    n = 5

    Comparator
    Absence of pegvisomant under nonfasting conditions
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Serum glucose before challenge
    4.2 mmol/L
    nonfasting pegvisomant blockade
    Serum glucose variability before challenge
    0.3 mmol/L
    nonfasting pegvisomant blockade, plus or minus
    Serum glucose after challenge
    6 mmol/L
    nonfasting pegvisomant blockade
    Serum glucose variability after challenge
    0.6 mmol/L
    nonfasting pegvisomant blockade, plus or minus
    P value
    < 0.05
    glucose, nonfasting pegvisomant blockade

    Source sentences

    Summary
    and glucose (4.2 +/- 0.3 vs. 6.0 +/- 0.6 mmol/L; P < 0.05) concentrations.
    3 context sentences
    Summary · context
    These changes were not observed under GHR blockade during fasting or in the absence of pegvisomant.
    Summary · context
    We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in fasting and nonfasting conditions.
    Summary · context
    Ten healthy subjects were enrolled in a double blind, placebo-controlled study on the effects of pegvisomant on GHRH and GH-releasing peptide-6 (GHRP-6)-induced GH secretion before and after 3 days of fasting and under nonfasting conditions (n = 5).
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy nonobese men, serum free fatty acids rapidly decreased during nonfasting pegvisomant blockade with GHRP-6, unlike conditions without pegvisomant.

    In plain wordsIn healthy men, free fatty acids fell during nonfasting pegvisomant blockade with GHRP-6, unlike conditions without pegvisomant.

    Peptide
    Pegvisomant
    Outcome
    DecreaseSerum free fatty acid response to GHRP-6
    Study

    n = 5

    Comparator
    Absence of pegvisomant under nonfasting conditions
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this group, a rapid decrease in serum free fatty acids levels was also observed.
    4 context sentences
    Summary · context
    Under the condition of GHR blockade by pegvisomant in the nonfasting state, GHRP-6 (1 microg/kg) caused a increase in serum insulin (10.3 +/- 2.1 vs. 81.3 +/- 25.4 mU/L; P < 0.001) and glucose (4.2 +/- 0.3 vs. 6.0 +/- 0.6 mmol/L; P < 0.05) concentrations.
    Summary · context
    These changes were not observed under GHR blockade during fasting or in the absence of pegvisomant.
    Summary · context
    We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in fasting and nonfasting conditions.
    Summary · context
    Ten healthy subjects were enrolled in a double blind, placebo-controlled study on the effects of pegvisomant on GHRH and GH-releasing peptide-6 (GHRP-6)-induced GH secretion before and after 3 days of fasting and under nonfasting conditions (n = 5).

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 04HumanNot a test of GHRP-6 aloneNon-randomized trialMechanism

    In nonfasting men under pegvisomant blockade, GHRP‑6 challenge increased serum insulin.

    In plain wordsIn men under pegvisomant blockade, a GHRP‑6 challenge raised insulin in the nonfasting state.

    Peptide
    GHRP-6
    Outcome
    IncreaseInsulin under nonfasting GHR blockade
    Study

    n = 5

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Serum insulin
    10.3 mU/L
    nonfasting, pegvisomant GHR blockade, GHRP-6 1 microg/kg; first value of reported pair (SE 2.1)
    Serum insulin
    81.3 mU/L
    nonfasting, pegvisomant GHR blockade, GHRP-6 1 microg/kg; second value of reported pair (SE 25.4)

    Source sentences

    Summary
    Under the condition of GHR blockade by pegvisomant in the nonfasting state, GHRP-6 (1 microg/kg) caused a increase in serum insulin (10.3 +/- 2.1 vs. 81.3 +/- 25.4 mU/L; P < 0.001) and glucose (4.2 +/- 0.3 vs. 6.0 +/- 0.6 mmol/L; P < 0.05) concentrations.
    1 context sentence
    Summary · context
    We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in fasting and nonfasting conditions.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 05HumanNot a test of GHRP-6 aloneNon-randomized trialMechanism

    In nonfasting men under pegvisomant blockade, GHRP‑6 challenge increased serum glucose.

    In plain wordsIn men under pegvisomant blockade, a GHRP‑6 challenge raised glucose in the nonfasting state.

    Peptide
    GHRP-6
    Outcome
    IncreaseGlucose under nonfasting GHR blockade
    Study

    n = 5

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Serum glucose
    4.2 mmol/L
    nonfasting, pegvisomant GHR blockade, GHRP-6 1 microg/kg; first value of reported pair (SE 0.3)
    Serum glucose
    6 mmol/L
    nonfasting, pegvisomant GHR blockade, GHRP-6 1 microg/kg; second value of reported pair (SE 0.6)

    Source sentences

    Summary
    Under the condition of GHR blockade by pegvisomant in the nonfasting state, GHRP-6 (1 microg/kg) caused a increase in serum insulin (10.3 +/- 2.1 vs. 81.3 +/- 25.4 mU/L; P < 0.001) and glucose (4.2 +/- 0.3 vs. 6.0 +/- 0.6 mmol/L; P < 0.05) concentrations.
    1 context sentence
    Summary · context
    We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in fasting and nonfasting conditions.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 06HumanNot a test of GHRP-6 aloneNon-randomized trialMechanism

    In nonfasting men under pegvisomant blockade, serum free fatty acids decreased rapidly after GHRP‑6 challenge.

    In plain wordsIn men under pegvisomant blockade, free fatty acids fell after GHRP‑6 challenge in the nonfasting state.

    Peptide
    GHRP-6
    Outcome
    DecreaseFree fatty acids under nonfasting GHR blockade
    Study

    n = 5

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    In this group, a rapid decrease in serum free fatty acids levels was also observed.
    2 context sentences
    Summary · context
    Under the condition of GHR blockade by pegvisomant in the nonfasting state, GHRP-6 (1 microg/kg) caused a increase in serum insulin (10.3 +/- 2.1 vs. 81.3 +/- 25.4 mU/L; P < 0.001) and glucose (4.2 +/- 0.3 vs. 6.0 +/- 0.6 mmol/L; P < 0.05) concentrations.
    Summary · context
    We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in fasting and nonfasting conditions.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 07HumanNot a test of GHRP-6 aloneNon-randomized trialMechanism

    In men, the GHRP‑6-associated rises in insulin and glucose and the fall in free fatty acids were not observed during fasting under GHR blockade or without pegvisomant.

    In plain wordsIn men, the insulin, glucose and fatty acid changes after GHRP‑6 were not seen during fasting under blockade or without pegvisomant.

    Peptide
    GHRP-6
    Outcome
    No significant changeInsulin, glucose and free fatty acid changes during fasting or without pegvisomant
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    These changes were not observed under GHR blockade during fasting or in the absence of pegvisomant.
    3 context sentences
    Summary · context
    Under the condition of GHR blockade by pegvisomant in the nonfasting state, GHRP-6 (1 microg/kg) caused a increase in serum insulin (10.3 +/- 2.1 vs. 81.3 +/- 25.4 mU/L; P < 0.001) and glucose (4.2 +/- 0.3 vs. 6.0 +/- 0.6 mmol/L; P < 0.05) concentrations.
    Summary · context
    In this group, a rapid decrease in serum free fatty acids levels was also observed.
    Summary · context
    We studied the roles of GH and the GHR using the GHR antagonist pegvisomant for metabolic control of healthy nonobese men in fasting and nonfasting conditions.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:34 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    21 Oct 2026, 15:58 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.